Related Experiment Video
Updated: Mar 24, 2026
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
The proteomics of lung injury in childhood: challenges and opportunities
Prue M Pereira-Fantini1, David G Tingay2
1Neonatal Research Group, Murdoch Childrens Research Institute, Royal Children's Hospital, Flemington Road, Parkville, VIC 3052 Australia ; Department of Paediatrics, University of Melbourne, Parkville, Australia.
Insights
Proteomics can identify early biomarkers for pediatric lung injury. Studies focusing on children are crucial, as adult data doesn't fully apply to pediatric lung diseases.
Area of Science:
- Biomedical research
- Proteomics
- Pediatric lung injury
Background:
- Proteomics, the study of proteins, is ideal for analyzing pediatric lung injury using accessible samples like plasma and bronchoalveolar lavage fluid.
- It offers potential for early biomarker discovery, pathway elucidation, and understanding protein changes in pediatric respiratory diseases.
- Despite its utility, proteomics is underutilized in pediatric injury research.
Purpose of the Study:
- To review the last decade of pediatric proteomic research in respiratory diseases.
- To highlight challenges specific to pediatric proteomic studies.
- To emphasize the need for pediatric-specific proteomic investigations.
Main Methods:
- Review of pediatric proteomic research over the past decade.
- Analysis of studies on bronchopulmonary dysplasia, respiratory infections, cystic fibrosis, and asthma.
- Consideration of challenges in pediatric proteomic research.
Main Results:
- Key pathological differences exist between pediatric and adult populations, limiting the direct application of adult study findings.
- Pediatric lung diseases exhibit significant variability in onset age and underlying mechanisms, necessitating tailored proteomic approaches.
- Well-designed studies with large, specific patient cohorts and matched controls are required.
Conclusions:
- Adult proteomic data cannot be reliably inferred for pediatric populations, underscoring the need for dedicated pediatric studies.
- The diverse nature of pediatric lung diseases requires robust, large-scale, disease-specific proteomic investigations.
- Pulmonary biomarkers are essential for predicting disease course, status, progression, and treatment response in children.
Abstract:
Proteomics, the large-scale study of the structure and function of proteins of a cell or organism, is a rapidly developing area of biomedical research which is perfectly suited to the study of pediatric lung injury, where a variety of samples are easily, and repeatedly, accessible including plasma (reflecting a whole body response) and broncheoalveolar lung fluid (reflecting the lungs response). When applied to pediatric lung injury, proteomics could be used to develop much needed early biomarkers of lung injury, elucidate pathological pathways and determine protein alterations associated with specific disease processes. However despite the obvious benefits and need, proteomics is rarely utilized in studies of pediatric injury. This review primarily reports on the last decade of pediatric research into proteomes associated with specific respiratory diseases including bronchopulmonary dysplasia, respiratory infection, cystic fibrosis and asthma whilst also reflecting on the challenges unique to proteomic studies of the pediatric respiratory disease population. We conclude that the number of key pathological differences between the pediatric and adult study populations inhibit inference of results from adult studies onto a pediatric population and necessitate studies of the pediatric proteome. Furthermore the disparity amongst pediatric lung disease in terms of age at onset and underlying pathological mechanism (genetic, immunological, intervention-based, developmental arrest, inhaled toxin) will require proteomic studies which are well designed, with large disease specific patient sets to ensure adequate power as well as matched controls. Regardless of causative agent, pulmonary biomarkers are needed to predict the clinical course of pediatric lung disease, status, progression and response to treatment. Identification of early biomarkers is particularly pertinent in order to understand the natural history of disease and monitor progression so prevention of ongoing lung injury and impact on childhood can targeted.
